Interestingly, an in vivo study demonstrated that combined menin-MLL and FLT3 inhibition showed a synergistic anti-leukemic effect on NPM1-mutated and FLT3-mutated AML [72]. Here, KMT2A is linked to acute myeloid leukemia.